Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has show
| Condition(s) | Stroke, Cerebrovascular Disorders, Brain Diseases, Nervous System Diseases, Vascular Diseases, Ischemic Stroke, Infarction, Medium Vessel Occlusion |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis. |
| Who can participate | Inclusion Criteria: * Age \> 18 years * Primary medium vessel occlusion (MeVO) or severe stenosis (≥70%) was detected on CTA, MRA, or DSA, involving arterial segments including M2-M3 of the middle cerebral artery (MCA), A1-A2 of the anterior cerebral artery (ACA), P1-P2 of the posterior cerebral artery (PCA), and the anterior inferior cerebellar artery (AICA), posterior inferior cerebellar artery (PICA), and superior cerebellar artery (SCA) * The clinical symptoms were consistent with MeVO, with a NIHSS score 5 - 25, or an NIHSS score of 3-4 in the presence of disabling neurological deficits (e.g., hemianopia, aphasia, or motor dysfunction) * Intra-arterial thrombolysis was administered within the following time windows: 1. Acute ischemic stroke within 24 hours of symptom onset or last kno |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | The Second Hospital of Anhui Medical University |
| Locations | Fuyang, Anhui, China; Fuyang, Anhui, China; Hefei, Anhui, China; Lu'an, Anhui, China; Liuzhou, Guangxi, China; Lishui, Zhejiang, China |
| Start date | 2026-01-06 |
| NCT ID | NCT07185022 |
| Official listing | https://clinicaltrials.gov/study/NCT07185022 |